1. 1-24 of 49 1 2 »
    1. Philips to acquire Volcano to expand global leadership position in image-guided therapy market

      Philips to acquire Volcano to expand global leadership position in image-guided therapy market

      Royal Philips (NYSE: PHG; AEX: PHIA) and Volcano Corporation (NASDAQ:VOLC), a global leader in catheter-based imaging and measurement solutions for cardiovascular applications, today announced that they have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Volcano for USD 18.00 per share, or a total equity purchase price of USD 1 billion (approx. EUR 800 million), to be paid in cash upon completion. The board of directors of Volcano has unanimously approved the transaction and recommends the offer to its shareholders ...

      Read Full Article
    2. Volcano Issues Statement Regarding Letter From Engaged Capital

      Volcano Issues Statement Regarding Letter From Engaged Capital

      Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, today confirmed receipt of a letter to its Board of Directors from Engaged Capital, LLC. The Company issued the following statement in response: Volcano welcomes the perspectives of its shareholders, and has a longstanding policy of open communications with all of our investors, includingEngaged Capital. The Company will carefully review and consider the ideas presented in the letter and continue its dialogue with Engaged Capital. The Volcano ...

      Read Full Article
    3. Volcano Corporation Presentation At Barclays Conference To Be Webcast

      Volcano Corporation Presentation At Barclays Conference To Be Webcast

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Barclays Global Healthcare Conference 2014 on Tuesday, March 11. The presentation by John Dahldorf, chief financial officer, will begin at 11:15 a.m., Eastern Daylight Time (8:15 a.m., Pacific Daylight Time). The presentation will be available through the conference website at http://cc.talkpoint.com/barc002/031114a_bc/?entity=52_3HS7I2G and via the company's website at www.volcanocorp.com . Volcano Corporation is ...

      Read Full Article
    4. Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis

      Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the fourth quarter and all of 2013. For the quarter ended December 31, 2013, Volcano reported revenues of $103.3 million versus revenues of $102.5 million in the same period a year ago. On a constant currency basis, revenues increased six percent year-over-year after adjusting for a negative impact of approximately $5.5 millionfrom foreign currency. Medical segment revenues increased approximately one percent and six percent on a ...

      Read Full Article
    5. Volcano Corporation Announces $200 Million Share Repurchase Authorization

      Volcano Corporation Announces $200 Million Share Repurchase Authorization

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that its Board of Directors has authorized a $200 million share repurchase program. The Company intends to fund share repurchases with cash on hand. As part of the program, Volcano will enter into a $100 million Accelerated Share Repurchase ("ASR") with J.P. Morgan Securities LLC ("JPMorgan"), as agent for JPMorgan Chase Bank, National Association, London Branch. Under the ASR agreement, Volcano will pay $100 million to JPMorgan and will receive ...

      Read Full Article
    6. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast

      Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Canaccord Genuity 2013 Medical Technology & Diagnostics Forum on Thursday, November 14. The presentation by John Dahldorf, chief financial officer, will begin at 10:30 a.m., Eastern Standard Time (7:30 a.m., Pacific Standard Time). The presentation will be available through http://wsw.com/webcast/canaccord12/ and via the company's website at www.volcanocorp.com . Volcano Corporation is revolutionizing the medical device ...

      Read Full Article
    7. Volcano Reports Third Quarter Results

      Volcano Reports Third Quarter Results

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the third quarter and first nine months of 2013. The company also today announced a strategic reprioritization and reallocation of resources within its distribution, research and development and clinical programs to focus on areas of strong projected growth in FFR (Fractional Flow Reserve), peripheral applications, coronary IVUS (Intravascular Imaging) driven by the ADAPT-DES clinical data and Axsun Medical. This has resulted in a corporate restructuring charge that reflects the ...

      Read Full Article
    8. Volcano Announces New Two-Year Results of Largest Prospective Study of Use of IVUS in Stent Placement

      Volcano Announces New Two-Year Results of Largest Prospective Study of Use of IVUS in Stent Placement

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced new two-year outcomes from an analysis of use of intravascular ultrasound (IVUS) in the ADAPT-DES ( A ssessment of D ual A nti P latelet T herapy with D rug- E luting S tents) Study, the largest prospective registry of IVUS use to date. Results suggest that, in the ADAPT-DES study, use of IVUS with angiography (compared with angiography alone) in placing the current generation of drug-eluting stents (DES) was associated with reductions ...

      Read Full Article
    9. Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014

      Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it expects revenues for the third quarter of 2013 on a reported basis will be approximately $95.8 million. This compares with revenues on a reported basis of $93.7 million in the same period a year ago. The company said that FX exchange rates had a negative impact of approximately $5.4 million compared to the third quarter a year ago. Medical segment revenues increased approximately three percent and ...

      Read Full Article
    10. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis

      Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the second quarter and first six months of 2013.

      For the quarter ended June 30, 2013, Volcano reported revenues of $101.3 million, an increase of six percent on a reported basis versus the same period a year ago and 12 percent on a constant currency basis after adjusting for a negative impact of approximately $5.5 million from foreign currency. Medical segment revenues increased more than seven percent ...

      Read Full Article
    11. Volcano Corporation Schedules First Quarter Conference Call, Webcast

      Volcano Corporation Schedules First Quarter Conference Call, Webcast

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the first quarter of fiscal 2013 on Thursday, May 2 . The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time ( 5 p.m., Eastern Daylight Time ), Thursday, May 2 , hosted by Scott Huennekens , president and chief executive officer, and John Dahldorf , chief financial officer. The teleconference can ...

      Read Full Article
    12. Volcano Corporation Provides Additional Guidance For 2013 (Impressive 65% Margins)

      Volcano Corporation Provides Additional Guidance For 2013 (Impressive 65% Margins)

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, is providing additional guidance for 2013 on an as reported basis to augment guidance provided on a constant currency basis in its fourth quarter 2012 earnings news release earlier today. On an as reported basis, based on foreign currency exchange rates as of February 21, 2013 , the company expects revenues will be in the range of $406-$412 million in 2013. Earlier today, the company provided guidance for revenues in 2013 in the ...

      Read Full Article
    13. Volcano Corporation Announces Record Preliminary Fourth Quarter 2012 Revenues

      Volcano Corporation Announces Record Preliminary Fourth Quarter 2012 Revenues

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it expects total revenues for the fourth quarter of 2012 will be approximately $102.5 million , bringing expected full year 2012 revenues to approximately $381.9 million . Medical segment revenues in the fourth quarter of 2012 increased approximately 10 percent on a reported basis and 12 percent on a constant currency basis versus the fourth quarter of 2011, driven by an increase in FFR (Fractional Flow Reserve) disposable revenues of ...

      Read Full Article
    14. Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.

      Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it has entered into a definitive agreement to acquire Sync-Rx Ltd., a privately-held company based in Israel that develops advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. It is anticipated the transaction will close within the next 30 days. "This transaction represents a strategic step in the advancement of our multi-modality platform," said Scott Huennekens , President and Chief Executive Officer of Volcano Corporation ...

      Read Full Article
    15. Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents

      Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents

      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that results from the largest study of its kind show that stent procedures guided by intravascular ultrasound (IVUS) resulted in better patient outcomes and fewer complications at 30 days and 12 months compared to procedures without IVUS, and were safe. Enrolling 3,349 patients, the IVUS sub-study is part of the Cardiovascular Research Foundation's (CRF) ADAPT-DES study (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents), a prospective, multi-center registry of ...

      Read Full Article
    16. Volcano Corporation Schedules Third Quarter Conference Call, Webcast

      Volcano Corporation Schedules Third Quarter Conference Call, Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the third quarter of fiscal 2012 on Tuesday, November 6 . The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time ( 5 p.m., Eastern Standard Time ), Tuesday, November 6 , hosted by Scott Huennekens , president and chief executive officer, and John Dahldorf , chief financial officer. The teleconference can ...

      Read Full Article
    17. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical

      Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a pressure sensing guide wire patent). Proceedings on damages have not yet been scheduled. In addition, a jury in the federal district court in Delaware has issued a verdict in St. Jude Medical's favor with respect to Volcano's patents at issue in the Company's ongoing patent lawsuit with St ...

      Read Full Article
    18. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast

      Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5.The presentation by John Dahldorf, chief financial officer, will begin at 9:10 a.m., Eastern Daylight Time (6:10 a.m., Pacific Daylight Time). The presentation will be available through the conference website at http://www.veracast.com/webcasts/stifel/healthcare2012/85103229.cfm and via the company's website at www.volcanocorp.com. Volcano ...

      Read Full Article
    19. Volcano Corporation Schedules Second Quarter Conference Call, Webcast

      Volcano Corporation Schedules Second Quarter Conference Call, Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the second quarter of fiscal 2012 on Thursday, August 2.The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Thursday, August 2, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. The teleconference can ...

      Read Full Article
    20. Volcano Corporation Presentation At Jefferies Conference To Be Webcast

      Volcano Corporation Presentation At Jefferies Conference To Be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Jefferies 2012 Global Healthcare Conference on Monday, June 4. The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). The presentation will be available through the conference website at http://wsw.com/webcast/jeff68/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporationis revolutionizing the medical device ...

      Read Full Article
    21. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast

      Volcano Corporation Presentation At JMP Securities Conference To Be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the 11th Annual JMP Securities Research Conference on Monday, May 14.The presentation by John Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific Daylight Time (1:30 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://www.wsw.com/webcast/jmp17/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporationis ...

      Read Full Article
    22. Volcano Corporation Presentation At Deutsche Bank Conference To Be Webcast

      Volcano Corporation Presentation At Deutsche Bank Conference To Be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8.The presentation by John Dahldorf, chief financial officer, will begin at 4:10 p.m., Eastern Daylight Time (1:10 p.m., Pacific Daylight Time).

      Read Full Article
    23. Volcano Corporation Presentation at Roth Conference to be Webcast

      Volcano Corporation Presentation at Roth Conference to be Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Roth Capital 24th Annual Orange County Growth Stock Conference on Monday, March 12. The presentation by John Dahldorf, chief financial officer, will begin at 9 a.m., Pacific Daylight Time (12 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://wsw.com/webcast/roth26/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporationis ...

      Read Full Article
    24. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast

      Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast

      Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will report its operating results for the fourth quarter of fiscal 2011 on Wednesday, February 22.The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time), Wednesday, February 22, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. The teleconference can ...

      Read Full Article
    1-24 of 49 1 2 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks